Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Mallinckrodt
Colorcon
Dow
Merck
Johnson and Johnson

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Choriogonadotropin alfa - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for choriogonadotropin alfa and what is the scope of freedom to operate?

Choriogonadotropin alfa is the generic ingredient in one branded drug marketed by Emd Serono and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Choriogonadotropin alfa has eighteen patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for choriogonadotropin alfa
International Patents:18
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 4
DailyMed Link:choriogonadotropin alfa at DailyMed
Recent Clinical Trials for choriogonadotropin alfa

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Sheba Medical CenterPhase 4
One FertilityPhase 2
Seoul National University HospitalN/A

See all choriogonadotropin alfa clinical trials

Pharmacology for choriogonadotropin alfa
Drug ClassGonadotropin

US Patents and Regulatory Information for choriogonadotropin alfa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for choriogonadotropin alfa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000   Start Trial   Start Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Baxter
AstraZeneca
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.